Skip to content
Medical Health Aged Care

Cure Brain Cancer Foundation Unveils Fellowship Awardees

Cure Brain Cancer Foundation 2 mins read

Pioneering Innovations in the Fight Against Cancer

SYDNEY, AUSTRALIA / ACCESSWIRE / June 30, 2023 / Cure Brain Cancer Foundation (CBCF) is pleased to announce the highly anticipated recipients of this year's prestigious Early Career Fellowships. This unrivaled funding opportunity is set to empower researchers, propelling them closer to breakthrough discoveries in the battle against brain cancer.

Designed to fuel cutting-edge research initiatives, CBCF research grants are championing advancements that hold the potential to revolutionize survival outcomes for individuals challenged by this formidable disease. From project grants to life-changing fellowships, this comprehensive program undertakes an unwavering commitment to addressing the urgent needs of the brain cancer community.

This round of CBCF grant funding is the first time ever that CBCF will be awarding two exceptional individuals: Andrew Garvie of Monash University and Dr. Alexander Davenport of Walter and Eliza Hall Medical Institute. CBCF grant monies, totaling over $1.4 million in the last 21 months, and the awarding of not one but two Early Career Fellowships in 2023, demonstrate the Foundation's commitment to supporting and empowering talented individuals in the field of cancer research.

"Today, we celebrate exceptional minds and groundbreaking projects that have the power to change lives," remarked Lance Kawaguchi, Chief Executive Officer for the Cure Brain Cancer Foundation. "These grants stand as a testament to our unwavering dedication to funding groundbreaking research that makes tangible progress in the relentless pursuit of a cure for cancer."

With this year's grant fellowship awards, innovative research initiatives will receive the vital resources they need to forge ahead with their life-saving endeavors for a duration of three years. By providing crucial funding and support for this extended period, CBCF remains at the vanguard of the fight against cancer, driving tangible impact and instilling hope in the hearts of patients and their families.

About Cure Brain Cancer Foundation

Cure Brain Cancer Foundation is an Australia-based non-profit organization that is working globally to rapidly improve disease survival through funding innovative brain cancer research. It is the largest dedicated funder of brain cancer research in Australia and has invested over $30 million into clinical trials and pre-clinical efforts across pediatric and adult brain cancers. The Foundation's mission is to unite the brain cancer community and rapidly increase patient survival and quality of life. For more information, visit https://www.curebraincancer.org.au/.

Contact Information

Melinda Koski
MK Public Relations
press@mkpublicrelations.co

SOURCE: Cure Brain Cancer Foundation

.


View source version on accesswire.com:
https://www.accesswire.com/764864/Cure-Brain-Cancer-Foundation-Unveils-Fellowship-Awardees

More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 17:07
JJP Biologics

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist,…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:54
NDARC

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.